Cargando…
Modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690893/ https://www.ncbi.nlm.nih.gov/pubmed/37439332 http://dx.doi.org/10.3324/haematol.2022.282521 |
| _version_ | 1785152619070619648 |
|---|---|
| author | Khan, Abdullah M. Dvorak, Kiatlyn Zhao, Qiuhong Bumma, Naresh Cottini, Francesca Devarakonda, Srinivas Umyarova, Elvira Sharma, Nidhi Benson, Don Rosko, Ashley |
| author_facet | Khan, Abdullah M. Dvorak, Kiatlyn Zhao, Qiuhong Bumma, Naresh Cottini, Francesca Devarakonda, Srinivas Umyarova, Elvira Sharma, Nidhi Benson, Don Rosko, Ashley |
| author_sort | Khan, Abdullah M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10690893 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-106908932023-12-02 Modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma Khan, Abdullah M. Dvorak, Kiatlyn Zhao, Qiuhong Bumma, Naresh Cottini, Francesca Devarakonda, Srinivas Umyarova, Elvira Sharma, Nidhi Benson, Don Rosko, Ashley Haematologica Letter to the Editor Fondazione Ferrata Storti 2023-07-13 /pmc/articles/PMC10690893/ /pubmed/37439332 http://dx.doi.org/10.3324/haematol.2022.282521 Text en Copyright© 2023 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letter to the Editor Khan, Abdullah M. Dvorak, Kiatlyn Zhao, Qiuhong Bumma, Naresh Cottini, Francesca Devarakonda, Srinivas Umyarova, Elvira Sharma, Nidhi Benson, Don Rosko, Ashley Modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma |
| title | Modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma |
| title_full | Modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma |
| title_fullStr | Modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma |
| title_full_unstemmed | Modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma |
| title_short | Modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma |
| title_sort | modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690893/ https://www.ncbi.nlm.nih.gov/pubmed/37439332 http://dx.doi.org/10.3324/haematol.2022.282521 |
| work_keys_str_mv | AT khanabdullahm modifiedcarfilzomibdosingisassociatedwithimprovedtreatmentresponsesandlongertimeontreatmentinpatientswithmultiplemyeloma AT dvorakkiatlyn modifiedcarfilzomibdosingisassociatedwithimprovedtreatmentresponsesandlongertimeontreatmentinpatientswithmultiplemyeloma AT zhaoqiuhong modifiedcarfilzomibdosingisassociatedwithimprovedtreatmentresponsesandlongertimeontreatmentinpatientswithmultiplemyeloma AT bummanaresh modifiedcarfilzomibdosingisassociatedwithimprovedtreatmentresponsesandlongertimeontreatmentinpatientswithmultiplemyeloma AT cottinifrancesca modifiedcarfilzomibdosingisassociatedwithimprovedtreatmentresponsesandlongertimeontreatmentinpatientswithmultiplemyeloma AT devarakondasrinivas modifiedcarfilzomibdosingisassociatedwithimprovedtreatmentresponsesandlongertimeontreatmentinpatientswithmultiplemyeloma AT umyarovaelvira modifiedcarfilzomibdosingisassociatedwithimprovedtreatmentresponsesandlongertimeontreatmentinpatientswithmultiplemyeloma AT sharmanidhi modifiedcarfilzomibdosingisassociatedwithimprovedtreatmentresponsesandlongertimeontreatmentinpatientswithmultiplemyeloma AT bensondon modifiedcarfilzomibdosingisassociatedwithimprovedtreatmentresponsesandlongertimeontreatmentinpatientswithmultiplemyeloma AT roskoashley modifiedcarfilzomibdosingisassociatedwithimprovedtreatmentresponsesandlongertimeontreatmentinpatientswithmultiplemyeloma |